儿童急性重症哮喘二线治疗:系统综述与荟萃分析
该系统综述纳入9项随机对照试验共546例18岁及以下儿童,评估静脉氨茶碱、短效β受体激动剂、硫酸镁、氯胺酮或皮下肾上腺素作为急性重症哮喘二线治疗的安全性和有效性。总体证据确定性低至极低,未显示任何静脉二线治疗优于其他方案;静脉硫酸镁在降低住院率、减少额外静脉用药和快速改善哮喘严重度评分方面显示一定优势,但证据质量有限。
要点
- 静脉氨茶碱在住院时长、额外静脉用药需求和干预后哮喘严重度评分方面与其他治疗无显著差异,但恶心呕吐更多。
- 静脉硫酸镁与较低住院率、减少额外静脉用药需求和更快速改善哮喘严重度评分相关。
- 总体证据确定性低至极低,无法确定任何静脉二线治疗方案的优越性。
核心结论
- 低至极低确定性证据表明,任何静脉二线治疗选项对急性哮喘均未显示优越性。
研究设计与样本
- 系统综述与荟萃分析,仅纳入随机对照试验,检索截至2024年5月,共纳入9项RCT、546例参与者。
主要发现
- 静脉氨茶碱组住院时长(小时)与其他治疗无显著差异(MD=-12.99,95%CI -33.13至7.15)。
- 静脉氨茶碱组额外静脉用药需求(RR=2.17,95%CI 0.48至9.71)和干预后哮喘严重度评分(MD=0.97,95%CI -0.91至2.85)与其他治疗相似。
- 静脉氨茶碱组恶心和呕吐更多见。
- 静脉SABA组住院时长(MD=-10.12,95%CI -45.74至25.49)和通气需求(RR=0.25,95%CI 0.03至2.21)无差异。
- 静脉硫酸镁组住院率更低(RR=1.52,95%CI 1.26至1.84)、额外静脉用药需求减少(RR=6.30,95%CI 2.62至15.17)且哮喘严重度评分快速改善(p<0.05)。
关键数值与推荐
- 纳入标准为随机对照试验,评估静脉氨茶碱、静脉SABA、静脉硫酸镁、静脉氯胺酮或皮下肾上腺素作为重症哮喘二线治疗。
- 结局包括发病率、升级治疗、住院时长、不良事件、死亡率和肺功能变化。
临床怎么用
- 临床决策需考虑证据确定性低,静脉硫酸镁显示一定获益但需结合具体临床情境。
- 静脉氨茶碱与更多恶心呕吐相关,使用时需监测不良反应。
局限性
- 证据确定性低至极低,限制了对二线治疗优越性的结论。
- 纳入研究数量有限(9项RCT),总样本量较小(546例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence regarding second-line treatment for severe asthma is limited. OBJECTIVES: To evaluate the safety and efficacy of intravenous aminophylline, intravenous short-acting beta agonist (SABA), intravenous magnesium sulphate, intravenous ketamine or subcutaneous adrenaline as a second-line treatment for severe asthma. METHODS: We included only randomised controlled trials (RCTs) and followed the international guidelines for conducting systematic reviews. We performed a comprehensive literature search up to May 2024. Outcomes included morbidity, escalation of care, length of hospital stay, adverse events, mortality and changes in lung functions. RESULTS: Nine RCTs were included (total participants=546). Compared with other treatments, intravenous aminophylline showed no significant difference in the duration of hospital stay in hours, except for critically ill ventilated patients who had a shorter stay (mean difference (MD)=-12.99, 95% CI -33.13 to 7.15). The need for additional intravenous medications (RR=2.17, 95% CI 0.48 to 9.71) and asthma severity scores postinterventions (MD=0.97, 95% CI -0.91 to 2.85) was similar. More nausea and emesis were observed in the intravenous aminophylline group. The intravenous SABA group showed no difference in hospital stay (MD=-10.12, 95% CI -45.74 to 25.49) or need for ventilation (RR=0.25, 95% CI 0.03 to 2.21). There were no frequent serious adverse events. The intravenous magnesium sulphate group had a lower hospitalisation rate (RR=1.52, 95% CI 1.26 to 1.84), reduced need for additional intravenous medication (RR=6.30, 95% CI 2.62 to 15.17) and a rapid improvement in asthma severity scores (p<0.05). CONCLUSION: There is low-to-very-low certainty evidence demonstrating the superiority of any intravenous second-line treatment options for acute asthma. PROSPERO REGISTRATION NUMBER: CRD42023405226.
引用
- Abdelgadir IS, Mudawi K, Hamud A, et al. Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials. Arch Dis Child. 2025. PMID: 40562457. doi:10.1136/archdischild-2024-327838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。